The 5q- Syndrome: Biology and Treatment

Overview

Journal Curr Treat Options Oncol

Specialty Oncology

Date 2011 Oct 4

PMID 21964863

Citations 4

Authors

Eric Padron

Rami Komrokji

Alan F List

Affiliations

Soon will be listed here.

Abstract

The 5q- syndrome is a myelodsyplastic syndrome (MDS) characterized by symptomatic anemia and an indolent natural history with low transformation potential. Our understanding of the molecular pathogenesis of this disease has advanced considerably, paralleled by the delineation of the relevant targets underlying selective lenalidomide sensitivity. The context in which one treats the 5q- syndrome, and all lower risk MDS, is critical. The focus of treatment should remain the amelioration of refractory cytopenias. In the 5q- syndrome, lenalidomide is the treatment of choice for patients with symptomatic anemia as it relieves the burden of transfusion dependence and iron overload in the majority of cases. We discuss herein the current understanding of the biology of the 5q- syndrome, actions of efficacy of lenalidomide and strategies for clinical management.

Citing Articles

Fungal Ribotoxins: A Review of Potential Biotechnological Applications.

Olombrada M, Lazaro-Gorines R, Lopez-Rodriguez J, Martinez-Del-Pozo A, Onaderra M, Maestro-Lopez M Toxins (Basel). 2017; 9(2).

PMID: 28230789 PMC: 5331450. DOI: 10.3390/toxins9020071.

Standardizing the initial evaluation for myelodysplastic syndromes.

Marshall D, Roboz G Curr Hematol Malig Rep. 2013; 8(4):361-9.

PMID: 24178514 DOI: 10.1007/s11899-013-0180-3.

Current therapy of myelodysplastic syndromes.

Zeidan A, Linhares Y, Gore S Blood Rev. 2013; 27(5):243-59.

PMID: 23954262 PMC: 4124605. DOI: 10.1016/j.blre.2013.07.003.

Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.

Syed Y, Scott L Drugs. 2013; 73(11):1183-96.

PMID: 23824699 DOI: 10.1007/s40265-013-0071-x.

References

Boultwood J, Fidler C, Strickson A, Watkins F, Gama S, Kearney L . Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002; 99(12):4638-41. DOI: 10.1182/blood.v99.12.4638. View

Zhao N, Stoffel A, Wang P, Eisenbart J, Espinosa 3rd R, Larson R . Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997; 94(13):6948-53. PMC: 21265. DOI: 10.1073/pnas.94.13.6948. View

Vasioukhin V, Bauer C, Degenstein L, Wise B, Fuchs E . Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell. 2001; 104(4):605-17. DOI: 10.1016/s0092-8674(01)00246-x. View

Dana S, Wasmuth J . Linkage of the leuS, emtB, and chr genes on chromosome 5 in humans and expression of human genes encoding protein synthetic components in human--Chinese hamster hybrids. Somatic Cell Genet. 1982; 8(2):245-64. DOI: 10.1007/BF01538680. View

Escoubet-Lozach L, Lin I, Jensen-Pergakes K, Brady H, Gandhi A, Schafer P . Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009; 69(18):7347-56. DOI: 10.1158/0008-5472.CAN-08-4898. View

Davies F, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y . Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001; 98(1):210-6. DOI: 10.1182/blood.v98.1.210. View

Jones T, BARKER H, da Cruz e Silva E, Mayer-Jaekel R, Hemmings B, Spurr N . Localization of the genes encoding the catalytic subunits of protein phosphatase 2A to human chromosome bands 5q23-->q31 and 8p12-->p11.2, respectively. Cytogenet Cell Genet. 1993; 63(1):35-41. DOI: 10.1159/000133497. View

List A, Baker A, Green S, Bellamy W . Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control. 2007; 13 Suppl:4-11. DOI: 10.1177/107327480601304s02. View

Pellagatti A, Cazzola M, Giagounidis A, Malcovati L, Della Porta M, Killick S . Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006; 108(1):337-45. DOI: 10.1182/blood-2005-12-4769. View

10.

Peng J, Kitchen S, West R, Sigler R, Eisenmann K, Alberts A . Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. Cancer Res. 2007; 67(16):7565-71. DOI: 10.1158/0008-5472.CAN-07-1467. View

11.

List A, Kurtin S, Roe D, Buresh A, Mahadevan D, Fuchs D . Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352(6):549-57. DOI: 10.1056/NEJMoa041668. View

12.

Lehmann S, OKelly J, Raynaud S, Funk S, Sage E, Koeffler H . Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007; 21(9):1931-6. DOI: 10.1038/sj.leu.2404852. View

13.

Pellagatti A, Jadersten M, Forsblom A, Cattan H, Christensson B, Emanuelsson E . Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007; 104(27):11406-11. PMC: 1892786. DOI: 10.1073/pnas.0610477104. View

14.

Swaroop A, Hogan B, Francke U . Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics. 1988; 2(1):37-47. DOI: 10.1016/0888-7543(88)90107-3. View

15.

Gould K, Moreno S, Tonks N, Nurse P . Complementation of the mitotic activator, p80cdc25, by a human protein-tyrosine phosphatase. Science. 1990; 250(4987):1573-6. DOI: 10.1126/science.1703321. View

16.

Verhelle D, Corral L, Wong K, Mueller J, Moutouh-de Parseval L, Jensen-Pergakes K . Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007; 67(2):746-55. DOI: 10.1158/0008-5472.CAN-06-2317. View

17.

Shibata H, Takano H, Ito M, Shioya H, Hirota M, Matsumoto H . Alpha-catenin is essential in intestinal adenoma formation. Proc Natl Acad Sci U S A. 2007; 104(46):18199-204. PMC: 2084320. DOI: 10.1073/pnas.0705730104. View

18.

Komrokji R, List A . Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am. 2010; 24(2):377-88. DOI: 10.1016/j.hoc.2010.02.013. View

19.

Coulthard L, White D, Jones D, McDermott M, Burchill S . p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009; 15(8):369-79. PMC: 3016890. DOI: 10.1016/j.molmed.2009.06.005. View

20.

Starczynowski D, Karsan A . Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle. 2010; 9(5):855-6. DOI: 10.4161/cc.9.5.11156. View